Foundation Medicine Inc (NASDAQ:FMI) COO Steven J. Kafka sold 5,774 shares of the stock in a transaction dated Wednesday, December 6th. The stock was sold at an average price of $58.57, for a total value of $338,183.18. Following the sale, the chief operating officer now directly owns 96,761 shares in the company, valued at $5,667,291.77. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Foundation Medicine Inc (NASDAQ FMI) traded down $0.60 during mid-day trading on Thursday, hitting $58.30. 306,400 shares of the stock traded hands, compared to its average volume of 232,342. The company has a debt-to-equity ratio of 0.47, a quick ratio of 2.03 and a current ratio of 2.24. Foundation Medicine Inc has a twelve month low of $17.10 and a twelve month high of $70.75.

Foundation Medicine (NASDAQ:FMI) last posted its earnings results on Wednesday, November 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.06) by $0.16. Foundation Medicine had a negative net margin of 119.69% and a negative return on equity of 143.18%. The business had revenue of $42.66 million for the quarter, compared to analyst estimates of $37.99 million. During the same period in the prior year, the company posted ($0.90) EPS. The company’s revenue for the quarter was up 45.0% on a year-over-year basis. sell-side analysts forecast that Foundation Medicine Inc will post -4.44 earnings per share for the current fiscal year.

Several hedge funds have recently bought and sold shares of the company. Legal & General Group Plc boosted its stake in shares of Foundation Medicine by 8.6% during the 2nd quarter. Legal & General Group Plc now owns 3,442 shares of the company’s stock worth $138,000 after acquiring an additional 274 shares in the last quarter. The Manufacturers Life Insurance Company boosted its stake in shares of Foundation Medicine by 3.0% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 11,747 shares of the company’s stock worth $467,000 after acquiring an additional 341 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Foundation Medicine by 1.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 61,597 shares of the company’s stock worth $2,449,000 after acquiring an additional 835 shares in the last quarter. Wells Fargo & Company MN boosted its stake in shares of Foundation Medicine by 8.8% during the 2nd quarter. Wells Fargo & Company MN now owns 11,510 shares of the company’s stock worth $458,000 after acquiring an additional 931 shares in the last quarter. Finally, Teachers Advisors LLC boosted its stake in shares of Foundation Medicine by 5.7% during the 1st quarter. Teachers Advisors LLC now owns 24,387 shares of the company’s stock worth $786,000 after acquiring an additional 1,316 shares in the last quarter. 33.44% of the stock is currently owned by institutional investors and hedge funds.

Several brokerages have weighed in on FMI. Zacks Investment Research raised Foundation Medicine from a “hold” rating to a “buy” rating and set a $66.00 price target on the stock in a research report on Wednesday. BidaskClub downgraded Foundation Medicine from a “buy” rating to a “hold” rating in a research report on Monday, September 18th. Three investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $45.33.

ILLEGAL ACTIVITY WARNING: “Foundation Medicine Inc (FMI) COO Sells $338,183.18 in Stock” was originally posted by American Banking News and is owned by of American Banking News. If you are viewing this report on another publication, it was stolen and republished in violation of U.S. and international trademark & copyright laws. The correct version of this report can be read at https://www.americanbankingnews.com/2017/12/07/foundation-medicine-inc-fmi-coo-sells-338183-18-in-stock.html.

Foundation Medicine Company Profile

Foundation Medicine, Inc is a molecular information company. The Company sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It is engaged in the business of delivering molecular information about cancer to its customers. Its platform includes various methods and algorithms for analyzing specimens across various types of cancer.

Insider Buying and Selling by Quarter for Foundation Medicine (NASDAQ:FMI)

Receive News & Ratings for Foundation Medicine Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foundation Medicine Inc and related companies with MarketBeat.com's FREE daily email newsletter.